** Shares of telehealth firm Hims & Hers HIMS.N fall 19.22% to $41.45 premarket
** Co says may no longer be able to sell compounded versions of Novo Nordisk's NOVOb.CO weight-loss drug Wegovy, after US FDA removes it from shortage list
** Adds the move could lead to customers cancelling their subscriptions, affecting revenue
** Shares have risen 5 fold in the last 12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.